A total of 75 adult patients were randomly assigned to receive engasertib 30mg, engasertib 40mg, or placebo (24, 25, and 26 patients, respectively) once daily for 12 weeks. HealthDay News — For adult ...
Talazoparib beyond BRCA: A phase II trial of talazoparib monotherapy in BRCA1 and BRCA2 wild-type patients with advanced HER2-negative breast cancer or other solid tumors with a mutation in homologous ...
Hereditary hemorrhagic telangiectasia, or Osler–Weber–Rendu syndrome, is an autosomal dominant vascular disorder that affects multiple systems. It is characterized by skin and mucosal telangiectasias ...
Mucin 16–Directed Therapy in Pediatric Sarcomas: Case Evidence of Ubamatamab Efficacy in Epithelioid Sarcoma and Its Implications for Other Sarcoma Subtypes We conducted a phase I trial of the ...
Hereditary hemorrhagic telangiectasia, previous known as Rendu–Oslar–Weber disease, is an autosomal dominant inherited disease characterized by telangiectasia of skin, mucous membrane and various ...
A 51-year-old woman with a 30-year history of recurrent epistaxis presented to the emergency department with a nosebleed. Her nosebleeds were initially mild but had gradually progressed in severity ...
Larrabee — Physician-in-Chief, First Medical Service, Boston City Hospital. Littman — Formerly Resident on the First Medical Service, Boston City Hospital. For records and addresses of authors see ...
A 42-year-old man presented with long-standing epistaxis, hemoptysis, and a hemoglobin level of 6 g per deciliter. He had a three-generation family history of HHT. The physical examination revealed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results